Semaglutide’s Promising Impact on Alcohol Use Disorder: A University Breakthrough
Semaglutide’s Promising Impact on Alcohol Use Disorder: A University Breakthrough In a groundbreaking collaboration between the University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences, a recent study has unveiled compelling evidence that semaglutide, a drug known for its FDA-approved applications in diabetes and weight loss, is associated with significant reductions in the symptoms of Alcohol Use Disorder (AUD). Published in The Journal of Clinical Psychiatry, this research presents the first human-based evidence of semaglutide’s potential impact on addictive behaviors. A Noteworthy Decrease in the Alcohol Use Disorders Identification Test scores The study, titled “Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series,” outlines outcomes from six patients who received semaglutide during weight loss treatment. Notably, the patients demonstrated a noteworthy decrease in th...